Last 7 days
-4.0%
Last 30 days
-13.8%
Last 90 days
-10.5%
Trailing 12 Months
4.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 304.8B | 1.4B | -3.73% | 61.04% | -152.12 | 215.28 | 20.37% | -37.45% |
ABBV | 275.0B | 58.1B | 0.21% | 1.63% | 23.24 | 4.74 | 3.30% | 2.55% |
REGN | 80.1B | 12.2B | -0.48% | 14.17% | 18.47 | 6.58 | -24.26% | -46.28% |
VRTX | 77.3B | 8.9B | -1.64% | 19.14% | 23.26 | 8.65 | 17.91% | 41.84% |
ALNY | 23.5B | 1.0B | -16.46% | 21.47% | -20.78 | 22.66 | 22.88% | -32.64% |
SRPT | 13.2B | 933.0M | 21.02% | 90.98% | -18.71 | 14.11 | 32.93% | -67.99% |
UTHR | 10.1B | 1.9B | -15.04% | 21.63% | 13.93 | 5.23 | 14.88% | 52.86% |
MID-CAP | ||||||||
MDGL | 4.5B | 504.0K | -6.48% | 165.34% | -15.07 | 2.5K | -66.53% | -22.12% |
RARE | 2.8B | 363.3M | -7.03% | -36.05% | -3.99 | 7.77 | 3.39% | -55.81% |
BPMC | 2.7B | 204.0M | 2.71% | -22.88% | -4.84 | 13.22 | 13.30% | 13.44% |
MRTX | 2.5B | 12.4M | -10.70% | -44.17% | -3.35 | 199.44 | - | -27.34% |
SMALL-CAP | ||||||||
CPRX | 1.6B | 191.8M | -7.72% | 90.19% | 24.49 | 8.55 | 43.59% | 60.82% |
MGNX | 429.6M | 93.0M | -0.16% | -22.78% | -2.25 | 4.62 | -19.83% | -30.37% |
CRBP | 24.0M | - | -31.83% | 665.59% | -0.57 | 19.11 | -77.61% | 7.22% |
CYTK | 3.5M | 94.6M | -15.04% | 9.81% | -0.01 | 0.04 | 34.30% | -80.65% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -32.9% | 587,367,000 | 875,483,000 | 848,809,000 | 840,768,000 | 810,456,000 |
S&GA Expenses | 7.4% | 150,295,000 | 139,945,000 | 136,622,000 | 159,275,000 | 186,347,000 |
EBITDA | -772.7% | -235,535,000 | 35,013,000 | -1,953,000 | 20,852,000 | - |
EBITDA Margin | -1102.7% | -0.40 | 0.04 | 0.00 | 0.02 | - |
Earnings Before Taxes | -2391.0% | -257,985,000 | 11,261,000 | -25,803,000 | -3,476,000 | -29,148,000 |
EBT Margin | -3514.6% | -0.44 | 0.01 | -0.03 | 0.00 | - |
Interest Expenses | -5.9% | 8,122,000 | 8,629,000 | 8,830,000 | 9,057,000 | 9,349,000 |
Net Income | -3784.2% | -269,722,000 | 7,321,000 | -28,153,000 | -3,893,000 | -28,597,000 |
Net Income Margin | -5591.6% | -0.46 | 0.01 | -0.03 | 0.00 | - |
Free Cahsflow | -351.3% | -290,091,000 | 115,428,000 | 86,502,000 | 40,923,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 4.6% | 2,534 | 2,422 | 2,456 | 2,519 | 2,612 |
Current Assets | 2.3% | 2,203 | 2,152 | 2,191 | 2,253 | 2,345 |
Cash Equivalents | -12.2% | 276 | 315 | 522 | 543 | 869 |
Inventory | 6.7% | 22.00 | 21.00 | 20.00 | 24.00 | 25.00 |
Net PPE | -58.9% | 74.00 | 181 | 177 | 178 | 178 |
Liabilities | 7.3% | 1,961 | 1,828 | 1,831 | 1,810 | 1,840 |
Current Liabilities | 9.9% | 312 | 283 | 268 | 228 | 241 |
Shareholder's Equity | -3.6% | 573 | 594 | 625 | 710 | 772 |
Retained Earnings | -3.8% | -1,429 | -1,377 | -1,330 | -1,225 | -1,159 |
Additional Paid-In Capital | 1.2% | 2,060 | 2,035 | 2,009 | 1,983 | 1,964 |
Accumulated Depreciation | - | 103 | - | - | - | - |
Shares Outstanding | 0.0% | 142 | 142 | 142 | 142 | 141 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -311.8% | -274 | 130 | 98.00 | 54.00 | 31.00 |
Share Based Compensation | 3.5% | 100 | 97.00 | 104 | 109 | 121 |
Cashflow From Investing | 30.8% | -262 | -379 | -73.77 | -171 | 195 |
Cashflow From Financing | 17.2% | -55.29 | -66.77 | -67.14 | 246 | 246 |
Buy Backs | NaN% | 0.00 | 0.00 | - | - | - |
90%
65.4%
21.1%
Y-axis is the maximum loss one would have experienced if Ionis Pharmaceuticals was unfortunately bought at previous high price.
-1.1%
-7.9%
-10.9%
FIve years rolling returns for Ionis Pharmaceuticals.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 19.15 | 4,959 | 329,959 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.05 | -102,725 | 596,275 | -% |
2023-03-10 | BAILLIE GIFFORD & CO | added | 2.75 | -1,760,830 | 12,607,200 | 0.01% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | unchanged | - | -88,306 | 516,694 | 0.03% |
2023-03-06 | Rockefeller Capital Management L.P. | unchanged | - | -17,000 | 97,000 | -% |
2023-02-28 | Voya Investment Management LLC | added | - | -453,638 | 2,654,360 | -% |
2023-02-24 | NATIXIS | added | 19.09 | 93,038 | 6,031,040 | 0.03% |
2023-02-24 | SRS Capital Advisors, Inc. | reduced | -59.46 | -1,433 | 567 | -% |
2023-02-21 | MACQUARIE GROUP LTD | unchanged | - | 17,000 | 4,110,000 | -% |
2023-02-21 | MACQUARIE GROUP LTD | added | 78.85 | 19,376,000 | 56,341,000 | 0.07% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | bb biotech ag | 6.8% | 9,635,000 | SC 13G/A | |
Feb 14, 2023 | t. rowe price investment management, inc. | 8.2% | 11,678,259 | SC 13G | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.54% | 13,546,694 | SC 13G/A | |
Feb 01, 2023 | blackrock inc. | 6.5% | 9,182,911 | SC 13G/A | |
Apr 11, 2022 | price t rowe associates inc /md/ | 10.1% | 14,350,460 | SC 13G/A | |
Feb 14, 2022 | price t rowe associates inc /md/ | 8.8% | 12,490,280 | SC 13G/A | |
Feb 11, 2022 | bb biotech ag | 7.2% | 10,232,973 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 8.50% | 12,007,076 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 4.15 -88.14% | 5.44 -84.46% | 11.00 -68.57% | 20.99 -40.03% | 25.62 -26.80% |
Current Inflation | 3.91 -88.83% | 5.05 -85.57% | 9.94 -71.60% | 18.60 -46.86% | 22.56 -35.54% |
Very High Inflation | 3.60 -89.71% | 4.55 -87.00% | 8.66 -75.26% | 15.76 -54.97% | 18.95 -45.86% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 8-K | Current Report | |
Feb 22, 2023 | 10-K | Annual Report | |
Feb 14, 2023 | 5 | Insider Trading | |
Feb 14, 2023 | SC 13G | Major Ownership Report | |
Feb 14, 2023 | SC 13G/A | Major Ownership Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-02-28 | O'NEIL PATRICK R. | acquired | 9,185 | 30.515 | 301 | evp clo & general counsel |
2023-02-28 | HOUGEN ELIZABETH L | acquired | 4,973 | 30.515 | 163 | evp, finance & cfo |
2023-02-28 | BENNETT C FRANK | acquired | 11,687 | 30.515 | 383 | evp, chief scientific officer |
2023-02-28 | Swayze Eric | acquired | 17,546 | 30.515 | 575 | evp research |
2023-02-28 | Geary Richard S | acquired | 17,546 | 30.515 | 575 | evp, chief development officer |
2023-02-06 | HOUGEN ELIZABETH L | sold | -84,392 | 40.5927 | -2,079 | evp, finance & cfo |
2023-02-06 | Cadoret-Manier Onaiza | sold | -58,996 | 40.6595 | -1,451 | evp, chf gl pdt str & oper ofc |
2023-02-06 | Geary Richard S | sold | -78,070 | 40.6615 | -1,920 | evp, chief development officer |
2023-02-06 | Schneider Eugene | sold | -57,464 | 40.6682 | -1,413 | evp, chf clinical develop ofcr |
2023-02-06 | BENNETT C FRANK | sold | -73,560 | 40.5738 | -1,813 | evp, chief scientific officer |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Revenue | $ 587,367 | $ 810,456 | $ 729,264 |
Expenses: | |||
Cost of sales | 14,116 | 10,842 | 11,947 |
Research, development and patent | 833,147 | 643,453 | 535,077 |
Selling, general and administrative | 150,295 | 186,347 | 354,322 |
Total operating expenses | 997,558 | 840,642 | 901,346 |
Loss from operations | (410,191) | (30,186) | (172,082) |
Other income (expense): | |||
Investment income | 25,331 | 10,044 | 30,562 |
Interest expense | (8,122) | (9,349) | (9,510) |
Gain (loss) on investments | (7,333) | 10,103 | 16,540 |
Gain on sale of real estate assets | 149,604 | 0 | 0 |
Other expenses | (7,274) | (9,760) | (62) |
Loss before income tax benefit (expense) | (257,985) | (29,148) | (134,552) |
Income tax benefit (expense) | (11,737) | 551 | (345,191) |
Net loss | (269,722) | (28,597) | (479,743) |
Net loss attributable to noncontrolling interest in Akcea Therapeutics, Inc. | 0 | 0 | 35,480 |
Net loss attributable to Ionis Pharmaceuticals, Inc. common stockholders | $ (269,722) | $ (28,597) | $ (444,263) |
Basic net loss per share (in dollars per share) | $ (1.9) | $ (0.2) | $ (3.18) |
Shares used in computing basic net loss per share (in shares) | 141,848 | 141,021 | 139,612 |
Diluted net loss per share (in dollars per share) | $ (1.9) | $ (0.2) | $ (3.18) |
Shares used in computing diluted net loss per share (in shares) | 141,848 | 141,021 | 139,612 |
Commercial Revenue [Member] | |||
Revenue: | |||
Revenue | $ 303,358 | $ 342,395 | $ 364,699 |
SPINRAZA Royalties [Member] | |||
Revenue: | |||
Revenue | 242,314 | 267,776 | 286,583 |
TEGSEDI and WAYLIVRA Revenue, Net [Member] | |||
Revenue: | |||
Revenue | 30,051 | 55,500 | 69,999 |
Licensing and Other Royalty Revenue [Member] | |||
Revenue: | |||
Revenue | 30,993 | 19,119 | 8,117 |
Research and Development Revenue [Member] | |||
Revenue: | |||
Revenue | 284,009 | 468,061 | 364,565 |
Collaborative Agreement Revenue [Member] | |||
Revenue: | |||
Revenue | 207,222 | 468,061 | 364,565 |
Eplontersen Joint Development Revenue [Member] | |||
Revenue: | |||
Revenue | $ 76,787 | $ 0 | $ 0 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 276,472 | $ 869,191 |
Short-term investments | 1,710,397 | 1,245,782 |
Contracts receivable | 25,538 | 61,896 |
Inventories | 22,033 | 24,806 |
Other current assets | 168,254 | 143,374 |
Total current assets | 2,202,694 | 2,345,049 |
Property, plant and equipment, net | 74,294 | 178,069 |
Right-of-use assets | 181,544 | 17,974 |
Deposits and other assets | 75,344 | 70,598 |
Total assets | 2,533,876 | 2,611,690 |
Current liabilities: | ||
Accounts payable | 17,921 | 11,904 |
Accrued compensation | 49,178 | 38,810 |
Accrued liabilities | 140,101 | 88,560 |
Income taxes payable | 6,249 | 36 |
Current portion of deferred contract revenue | 90,577 | 97,714 |
Other current liabilities | 7,535 | 3,526 |
Total current liabilities | 311,561 | 240,550 |
Long-term deferred contract revenue | 287,768 | 351,879 |
Long-term lease liabilities | 178,941 | 19,432 |
Long-term mortgage debt | 8,847 | 59,713 |
Long-term obligations | 7,126 | 6,946 |
Total liabilities | 1,960,989 | 1,839,953 |
Stockholders' equity: | ||
Common stock, $0.001 par value; 300,000,000 shares authorized, 142,057,736 and 141,210,015 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively | 142 | 141 |
Additional paid-in capital | 2,059,850 | 1,964,167 |
Accumulated other comprehensive loss | (57,480) | (32,668) |
Accumulated deficit | (1,429,625) | (1,159,903) |
Total stockholders' equity | 572,887 | 771,737 |
Total liabilities and stockholders' equity | 2,533,876 | 2,611,690 |
0 Percent Convertible Senior Notes [Member] | ||
Current liabilities: | ||
Convertible senior notes, net | 622,242 | 619,119 |
0.125 Percent Convertible Senior Notes [Member] | ||
Current liabilities: | ||
Convertible senior notes, net | $ 544,504 | $ 542,314 |